Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure

Title: Real-world Effectiveness and Safety of Tofacitinib in Multi-Refractory Ulcerative Colitis: insights from a Belgian Cohort with prior Anti-TNF and Vedolizumab Exposure
Authors: Cremer, A.; Mansour, A.; Lobaton, T.; Bossuyt, P.; Rahier, J.; Baert, F.; Dewit, O.; Macken, E.; Vijverman, A.; Van Hootegem, P.; Mana, F.; Willandt, B.; Humblet, E.; D'Heygere, F.; Verreth, A.; El Nawar, A.; COENEGRACHTS, Jean-Louis; Dewit, S.; De Coninck, S.; Schoofs, N.; Delen, S.; Dutre, J.; Thienpont, C.; Vanden Branden, S.; Staessen, D.; Croone, C.; Vieujean, S.; Franchimont, D.
Contributors: Cremer, A.; Mansour, A.; Lobaton, T.; Bossuyt, P.; Rahier, J.; Baert, F.; Dewit, O.; Macken, E.; Vijverman, A.; Van Hootegem, P.; Mana, F.; Willandt, B.; Humblet, E.; D'Heygere, F.; Verreth, A.; El Nawar, A.; COENEGRACHTS, Jean-Louis; Dewit, S.; De Coninck, S.; Schoofs, N.; Delen, S.; Dutre, J.; Thienpont, C.; Vanden Branden, S.; Staessen, D.; Croone, C.; Vieujean, S.; Franchimont, D.
Publisher Information: Vzw/asbl Acta Gastro-Enterologica Belgica
Publication Year: 2025
Collection: Document Server@UHasselt (Universiteit Hasselt)
Subject Terms: efficacy; inflammatory bowel disease; JAK inhibitor
Description: Background and aims: Tofacitinib has expanded treatment options for moderate-to-severe ulcerative colitis (UC). Longterm real-world data on its efficacy and safety remain limited, particularly in multi-refractory populations. This study evaluated the real-world effectiveness and safety of tofacitinib in Belgian UC patients with prior exposure to anti-TNF and vedolizumab. Patients and methods: This retrospective multicentric observational study included consecutive adult UC patients from 26 Belgian centers who initiated tofacitinib through an early access program (November 2018-August 2019). Data were prospectively collected. Primary endpoint was clinical remission (partial adapted Mayo score
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
Relation: https://hdl.handle.net/1942/47763; 237; 229; 88; 001604448600001
DOI: 10.51821/88.3.14064
Availability: https://hdl.handle.net/1942/47763; https://doi.org/10.51821/88.3.14064
Rights: Acta Gastro-Enterologica Belgica. Free access ; info:eu-repo/semantics/openAccess
Accession Number: edsbas.A3BFB409
Database: BASE